利培酮对首发精神分裂症S100B蛋白含量影响与疗效关系

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (3): 313-317.

利培酮对首发精神分裂症S100B蛋白含量影响与疗效关系

刘林晶¹, 修梅红², 张向阳², 陈大春²

¹温州康宁医院精神科,温州 3250072,浙江;
²北京回龙观医院精神科,北京 100096

收稿日期:2011-11-25 修回日期:2012-02-17 出版日期:2012-03-26 发布日期:2012-04-20
通讯作者: 陈大春,男,教授,主任医师,研究方向:精神生化及精神药理。Tel: 13520506068, E-mail: cdc1963@sina.com
作者简介:刘林晶,女,本科,主治医师,研究方向:精神病学。Tel: 13616775093, E-mail: llj0822@163.com

Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients

LIU Lin-jing¹, XIU Mei-hong², ZHANG Xiang-yang², CHEN Da-chun²

¹Wenzhou Kangning Hospital, Wenzhou 325007, Zhejiang, China;
²Beijing Huilongguan Hospital, Beijing 100000, China

Received:2011-11-25 Revised:2012-02-17 Online:2012-03-26 Published:2012-04-20

摘要/Abstract

摘要： 目的: 探讨首发精神分裂症S100B蛋白是否异常;利培酮对S100B影响与疗效之间关系。方法: 收集符合美国精神障碍诊断与统计手册第4版诊断标准首发精神分裂症住院患者53例,正常对照58例。患者组单一利培酮治疗12周,阳性和阴性综合症量表(positive and negative syndrome scale, PANSS)、临床总体印象量表(clinical general impression, CGI)、汉密尔顿抑郁量表(hamiton depression rating scale, HAMD)评定病情,酶联免疫吸附法(enzyme linked immunosorbent assay, ELISA)检测研究对象的S100B含量。结果: 基线患者组的S100B蛋白含量显著高于正常对照组(P<0.01)。12周利培酮治疗后S100B含量显著低于治疗前,但仍高于正常对照(P<0.05)。基线S100B蛋白含量与发病年龄、HAMD评分呈显著负相关(r=-0.22, -0.23, P均<0.05);治疗后S100B蛋白含量有效组低于无效组,与治疗前后PANSS减分值、阴性症状减分值呈显著负相关(r=-0.28、-0.31, P均<0.05)。结论: 首发精神分裂症S100B含量显著高于正常对照;利培酮治疗降低S100B含量且与临床疗效有一定的相关性;精神分裂症患者中枢神经系统可能存在着结构性损伤。

关键词: 精神分裂症, S100B蛋白, 利培酮, 疗效

Abstract: AIM: To study if S100B levels is abnormity, to study the effect of risperidone on S100B levels and relationship between S100B levels and treatment response in first-episode schizophrenic patients. METHODS: Fifty-three first-episode schizophrenia inpatients according to DSM-IV were treated only with risperidone for 12 weeks, the Positive and Negative Syndrome Scale (PANSS), Clinical General Impression (CGI) and Hamiton Depression Rating Scale (HAMD) were estimated at the baseline and the endpoint to evaluate the clinical efficacy. The serum S100B levels of the patients at the baseline and the endpoint and the 58 healthy controls were assayed using Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: The serum S100B levels of the patients groups were significantly higher than the controls (P<0.01) at the baseline, were significantly decreased after 12 weeks treatment with risperidone but remained significantly higher than controls (P<0.05). The serum S100B levels was negative correlated with the age of onset and score of HAMD(r= -0.28, -0.31, P all <0.05)at baseline, The serum S100B levels were significantly lower in the treatment responders comparing no-responders, were negative correlated with reduction of PANSS total score and negative subscore from baseline to 12 weeks (r=-0.28, -0.31, P all <0.05). CONCLUSION: The serum S100B levels of the schizophrenic patients are significantly higher than the healthy controls, Risperidone treatment reduced the S-100B levels that were associated with treatment response, indicating that patients with schizophrenia may suffer structural damage in central nervous system.

Key words: Schizophrenia, S100B, Risperidone, Treatment-response

中图分类号:

R749.3

刘林晶, 修梅红, 张向阳, 陈大春. 利培酮对首发精神分裂症S100B蛋白含量影响与疗效关系[J]. 中国临床药理学与治疗学, 2012, 17(3): 313-317.

LIU Lin-jing, XIU Mei-hong, ZHANG Xiang-yang, CHEN Da-chun. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 313-317.

参考文献

[1] Steiner J, Bernstein HG, Bielau H,et al. S100B immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study[J]. J Psychiatr Res, 2008, 42(10): 868-876.
[2] Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca²⁺ binding protein S100B: role in D2 receptor function[J]. Mol Pharmacol, 2008, 74(2): 371-378.
[3] Esposito G, De Filippis D, Cirillo C, et al. The astroglial-derived S100B eta protein stimulates the expression of nitric oxide synthase in rodent macrophages through p38 MAP kinase activation[J]. Life Sci, 2006, 78(23): 2707-2715.
[4] ZhangXY, Xiu MH, Song C, et al. Increased serum S100B in never-medicated and medicated schizophrenic patients [J]. J Psychiatr Res, 2010, 44(16): 1236-1240.
[5] 韩笑乐,谭云龙,杨甫德,等.首发未服药精神分裂症患者血清S100B蛋白浓度变化[J]. 中国神经精神疾病杂志, 2009, 35(11): 655-657.
[6] Qi LY, Xiu MH, Chen DC, et al. Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics[J]. Neurosci Lett, 2009, 462(2): 113-117.
[7] Steiner J, Walter M, Wunderlich MT, et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE[J]. Biol Psychiatry, 2009, 65(12): 1107- 1110.
[8] Tramontina F, Tramontina AC, Souza DF, et al. Glutamate uptake is stimulated by extracellular S100B in hippocampal astrocytes [J]. Cell Mol Neurobiol, 2006, 26(1): 81-86.
[9] Buttner T, Weyers S, Postert T, et al. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction[J]. Stroke, 1997, 28 (10): 1961-1965.
[10] Van Eldik LJ, Griffin WS. S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions [J]. Biochim Biophys Acta, 1994, 1223(3): 398-403.
[11] Asli S, Selcuk K, Cengiz AK, et al. Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31(6): 1164-1169.
[12] Steiner J, Bernstein HG, Bogerts B, et al. Haloperidol and clozapine decrease S100B release from glial cells [J]. Neuroscience, 2010, 167(4): 1025-1031.
[13] Ling S H, Tang YL, Jiang F, et al. Plasma S-100B protein in Chinese patients with schizophrenia: Comparison with healthy controls and effect of antipsychotics treatment[J]. J Psychiatric Res, 2007, 41(1/2): 36- 42.
[14] Rothermundt M, Ponath G, Glaser T, et al. S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia[J]. Neuropsychopharmacology, 2004, 29(5): 1004- 1011.
[15] Rothermundt M, Missler U, Arolt V, et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology[J]. Mol Psychiatry, 2001, 6(4): 445-449.